BCL2 inhibition in double hit lymphoma
- PMID: 25407655
- DOI: 10.3109/10428194.2014.987769
BCL2 inhibition in double hit lymphoma
Comment on
-
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.Leuk Lymphoma. 2015 Jul;56(7):2146-52. doi: 10.3109/10428194.2014.981172. Epub 2015 Jan 28. Leuk Lymphoma. 2015. PMID: 25373508